Abstract:Background The purpose of the present study was to investigate the effect of metformin combined with alendronate on subchondral bone and cartilage degeneration in a destabilization of the medial meniscus (DMM)-induced osteoarthritis (OA) mouse model. Method The effect of metformin on OA was assessed by H&E, safranin O/fast green, immunohistochemical and tartrate-resistant acid phosphatase (TRAP) staining. The Osteoarthritis Research Society International (OARSI) criteria were used to grade the degeneration of articular cartilage. ATDC5 cells were stimulated with 10 ng/mL IL-1β to establish an in vitro model of OA. Bone marrow macrophages were isolated. Cell proliferation was examined using CCK-8 assays. Cartilage extracellular matrix degradation was analyzed using Alcian Blue staining and high-density culture. Osteoclastogenesis was analyzed using TRAP staining. The mitochondrial membrane potential of ATDC5 cells and osteoclasts was determined by JC-1 fluorescent staining. Immunostaining, RT–PCR, and western blot analyses were carried out to examine protein and RNA expression levels. Result There were lower OARSI scores and fewer TRAP-positive cells in DMM mice after treatment with metformin combined with alendronate. In cartilage, metformin inhibited the expression of MMP3 and MMP13 in IL-1β-stimulated OA chondrocytes and increased the expression of Sox9 and aggrecan. In parallel, metformin also inhibited cartilage matrix degradation, as shown by Alcian blue staining and SO/FG staining in ATDC5 cells and cartilage tissues. Moreover, metformin and alendronate downregulated the levels of specific genes and proteins (NFATc1, c-Fos, DC-STAMP, TNFRSF11, CTSK), thereby inhibiting osteoclast differentiation in vitro. Mechanistically, metformin increased the expression of phospho-AMPK alpha1, attenuated the phosphorylation of NF-κB, and reduced reactive oxygen species (ROS) levels. Conclusion Metformin combined with alendronate may be a useful candidate for attenuating early-stage OA. This would be an ideal drug/drug combination for treating osteoarthritis in the presence of osteoporosis combined with T2D.

Metformin Attenuates the Inflammatory Response Via the Regulation of Synovial M1 Macrophage in Osteoarthritis

Metformin Attenuates Osteoarthritis by Targeting Chondrocytes, Synovial Macrophages and Adipocytes

Metformin attenuates cartilage degeneration in an experimental osteoarthritis model by regulating AMPK/mTOR

Metformin Attenuates Monosodium-Iodoacetate-Induced Osteoarthritis via Regulation of Pain Mediators and the Autophagy–Lysosomal Pathway

Metformin mitigates osteoarthritis progression by modulating the PI3K/AKT/mTOR signaling pathway and enhancing chondrocyte autophagy

Metformin reduces chondrocyte pyroptosis in an osteoarthritis mouse model by inhibiting NLRP3 inflammasome activation

Metformin Exhibits Anti-Inflammatory Effects by Regulating microRNA-451/CXCL16 and B Cell Leukemia/Lymphoma 2 in Patients With Osteoarthritis

Metformin Limits Osteoarthritis Development and Progression Through Activation of AMPK Signalling

Metformin Combined with Alendronate Ameliorates Osteoarthritis by Attenuating RANKL-Induced Bone Resorption and Protecting Cartilage Against Degradation

Exploration of Metformin As Novel Therapy for Osteoarthritis: Preventing Cartilage Degeneration and Reducing Pain Behavior

Metformin Augments Anti-Inflammatory and Chondroprotective Properties of Mesenchymal Stem Cells in Experimental Osteoarthritis

Metformin inhibits knee osteoarthritis induced by type 2 diabetes mellitus in rats: S100A8/9 and S100A12 as players and therapeutic targets

Metformin Inhibits Advanced Glycation End Products-Induced Inflammatory Response in Murine Macrophages Partly through AMPK Activation and RAGE/NFκB Pathway Suppression.

Metformin Inhibits Inflammation and Bone Destruction in Collagen- Induced Arthritis in Rats

Metformin enhances osteogenic differentiation of BMSC by modulating macrophage M2 polarization

Metformin suppresses UHMWPE particle-induced osteolysis in the mouse calvaria by promoting polarization of macrophages to an anti-inflammatory phenotype

AMPK Activator Decelerates Osteoarthritis Development by Inhibition of Β-Catenin Signaling in Chondrocytes

Metformin Shows Anti‐inflammatory Effects in Murine Macrophages Through Dicer/microribonucleic Acid‐34a‐5p and Microribonucleic Acid‐125b‐5p

Role of metformin in inflammation

Metformin Inhibits Chemokine Expression Through the AMPK/NF-κB Signaling Pathway.

RETRACTED: Metformin Ameliorates Senescence of Adipose-Derived Mesenchymal Stem Cells and Attenuates Osteoarthritis Progression via the AMPK-Dependent Autophagy Pathway (Retracted Article)